p38 Mitogen-activated protein kinase (p38 MAPK) and NADPH Oxidase (NOX) are cytoprotective determinants in the trophozoite-induced apoptosis of peripheral blood mononuclear cells.
In a host-parasite interaction model, peripheral blood mononuclear cells (PBMCs) were co-incubated with trophozoites of Entamoeba histolytica to determine if the cytotoxic killing of PBMCs involves (NOX)-derived reactive oxygen species (ROS) and p38 mitogen-activated protein kinase (MAPK). Experimental PBMC populations were pre-treated with diphenylene iodonium chloride to inhibit NOX, N-acetylcysteine to inhibit p47(phox) (a subunit of NOX), and SB202190 to inhibit p38 MAPK, with co-suppression of caspases. Percentage apoptosis, caspase-3 activity and ROS generation were monitored in all PBMC populations. Pre-treatment significantly raised the proportion of apoptotic PBMCs, but changes in caspase-3 activity and ROS production were relatively negligible. These results indicate that p38 MAPK and NOX were cytoprotective determinants in the trophozoite-induced apoptosis of PBMCs. Further, the programmed cell death herein investigated was independent of both caspases and ROS, and the exact mechanism of cell death remains to be an open question.
Diliman, Quezon City, Philippines. u238_2010@hotmail.com
Leonardo P
LP
Dingayan
D000111:Acetylcysteine / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology; D053148:Caspase 3 / Q000276:immunology* / Q000378:metabolism; D061945:Caspase Inhibitors; D002478:Cells, Cultured; D019610:Cytoprotection / Q000187:drug effects / Q000276:immunology; D004748:Entamoeba histolytica / Q000276:immunology*; D004749:Entamoebiasis / Q000276:immunology* / Q000378:metabolism / Q000469:parasitology; D006790:Host-Parasite Interactions / Q000276:immunology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D020287:In Situ Nick-End Labeling; D007963:Leukocytes, Mononuclear / Q000276:immunology* / Q000378:metabolism / Q000469:parasitology; D019255:NADPH Oxidases / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000378:metabolism; D009861:Onium Compounds / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D017382:Reactive Oxygen Species / Q000276:immunology / Q000378:metabolism; D013053:Spectrophotometry; D053058:Trophozoites / Q000276:immunology*; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000378:metabolism
D061945:Caspase Inhibitors; D007093:Imidazoles; D009861:Onium Compounds; D011725:Pyridines; D017382:Reactive Oxygen Species; C007517:diphenyleneiodonium; D019255:NADPH Oxidases; C060505:neutrophil cytosolic factor 1; D048051:p38 Mitogen-Activated Protein Kinases; D053148:Caspase 3; C090942:4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole; D000111:Acetylcysteine